Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol-Enhanced MRI for Lymph Nodes in Rectal Cancer
NCT03280277Phase 1Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Apr 2018
- Primary completion
- Aug 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ferumoxytol in rectal cancer, sponsored by OHSU Knight Cancer Institute. Primary endpoints: Practical feasibility of administering ferumoxytol and obtaining images up to 6 weeks and Technical feasibility of USPIO-MRI up to 6 weeks. Started Apr 2018; status: terminated.
02
Drugs
ferumoxytol
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03280277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03280277.